Genentech (NYSE:DNA) formerly known as (NYSE:GNE)

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Genentech (NYSE:DNA) formerly known as (NYSE:GNE)

An SI Board Since July 1999

Posts	SubjectMarks	Bans	Symbol
250	46	0	DNA

Emcee: esecurities(tm)	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
150	The lower dosage which translates into lower cost, would cause more users to use	amoezzi	-	6/2/2007
149	A couple of items from the WSJ health blog: <i>Results from a study of Av	tom pope	-	6/2/2007
148	ML: ASCO ‘07: Competitive Issues for DNA Likely Overblown Competition to Herce	tom pope	-	5/30/2007
147	CJ You need to change your handle once again!	Brinks	-	4/21/2007
146	Genentech Extends Stock Repurchase Program Friday April 20, 4:08 pm ET SOUTH S	249443	-	4/20/2007
145	Cancer-Drug Avastin Gives Genentech Results a Boost By PAULA L. STEPANKOWSKY Ap	Doc Bones	-	4/12/2007
144	Avastin has finally become DNA’s biggest-selling drug: investorshub.com	DewDiligence_on_SI	-	4/11/2007
143	Getting Ahead of Genentech [Fast Money - CNBC] Posted By:Carlo Dellaverson Comp	Doc Bones	-	4/11/2007
142	>>Despite FDA Black Box Warning and Restriction to Second-Line Use, Clinic	tuck	-	3/26/2007
141	Merrill: Guidance In-line, Pipeline Emerges; Avastin Halt Not a Concern There w	tom pope	-	3/26/2007
140	The euphoria seems to remain in the stock valuation. Insider ownership didn'	Qualified Opinion	-	3/23/2007
139	The euphoria didn't last long. The word "flat" is a killer. <i	tom pope	-	3/23/2007
138	Color on JP Morgan call regarding upcoming investor meeting on 3/23: notablecal	tuck	-	3/20/2007
137	LinkRoche says low-dose Avastin works for lung cancer, which may impact revenue	Qualified Opinion	-	2/22/2007
136	BLIND AMBITION Genentech's Big Drug For Eyes Faces a Rival Intended for Ot	Doc Bones	-	2/22/2007
135	tom...I've never seen so many people so thrilled with a 95% loss in a positi	boomer123	-	1/29/2007
134	Thanks, Boomer. I have SPRL bookmarked because it's the best example I'v	tom pope	-	1/26/2007
133	tom pope...thought I would let you know I got your private reply regarding SPRL.	boomer123	-	1/26/2007
132	Merrill - maintain buy. Lowering Lucentis Sales Estimate We lowered our ’07 Luc	tom pope	-	1/26/2007
131	Message 23172212	DewDiligence_on_SI	-	1/10/2007
130	Revenue and compensation both a little higher than I expected. Guidance for	tuck	-	1/10/2007
129	>>Genentech Announces Full Year and Fourth Quarter 2006 Results PR Newswi	tuck	-	1/10/2007
128	Merrill, going out on a bit of a limb before earnings: Revenue Upside Likely: D	tom pope	-	1/10/2007
127	Quite interesting(for me, anyway)Justice Scalia delivered the opinion of the Cou	zeta1961	-	1/9/2007
126	It seems a lot of folks are lining up to take a swing at Cabilly 2, including th	tuck	-	1/9/2007

Go to reply# or date (mm/dd/yy):